Has Stephanie Booth, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,377 in general payments to Stephanie Booth, MD across 50 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephanie Booth, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephanie Booth, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephanie Booth, MD

Rheumatology · Austin, TXNPI 1356300990

Payments from drug & device makers

$1,377in general payments, 2019–2025

Across 50 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$821
Amgen$184
Johnson & Johnson$152
Aurinia Pharma U.S., Inc.$108
UCB, Inc.$86
Pfizer$26

What the payments were for

Food & beverage$1,34698%
Education$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	32	$821
Amgen	3	$184
Johnson & Johnson	10	$152
Aurinia Pharma U.S., Inc.	2	$108
UCB, Inc.	2	$86
Pfizer	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rinvoq$341
Otezla$125

How this compares

$1,377 in reported general payments places this provider in the 30th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas →

Medicare billing

Part B allowed, 2024

$1,052,502

Medicare patients

Services billed

89,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EnbrelEtanercept	22	$190,247
Humira(Cf)Adalimumab	25	$187,318
Enbrel SureclickEtanercept	21	$179,934
RinvoqUpadacitinib	17	$146,971
OtezlaApremilast	12	$56,001
Cevimeline Hcl	15	$4,598
Hydroxychloroquine Sulfate	103	$3,627
MethotrexateMethotrexate Sodium	79	$1,949
Leflunomide	28	$1,171
Pilocarpine Hcl	13	$881
Sulfasalazine	17	$464
Celecoxib	15	$298
Prednisone	23	$186
Methotrexate SodiumMethotrexate Sodium/Pf	16	$181
Allopurinol	11	$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieHumira(Cf), Rinvoq	$821	$334,28842 claims
AmgenEnbrel, Otezla	$184	$246,24834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Austin

Paul PickrellAustin$40.9M
Anurekha ChadhaAustin$1.9M
Tina BunchAustin$974K
Atul SinghalMesquite$13.9M
Shaikh AliTomball$9.8M
Jitendra VasandaniLubbock$6.4M
Dhiman BasuColleyville$6.2M
Tamar BrionezThe Woodlands$5.2M
Philip WallerHouston$4.9M
John CushDallas$3.9M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →